Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: A single centre experience and review of the literature

Annals of Oncology

Volumn 28, Issue 2, 2017, Pages 377-385

  Spain, L ^a   Walls, G ^a   Julve, M ^a   O'Meara, K ^a   Schmid, T ^a   Kalaitzaki, E ^a   Turajlic, S ^a,b   Gore, M ^a   Rees, J ^c   Larkin, James ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b THE FRANCIS CRICK INSTITUTE   (United Kingdom)

^c NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

Anti CTLA 4; Anti PD 1; Immune related adverse event; Melanoma; Neurological toxicity

Indexed keywords

CORTICOSTEROID; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; IPILIMUMAB; NIVOLUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 RECEPTOR ANTIBODY; RECEPTOR ANTIBODY; UNCLASSIFIED DRUG; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADVANCED CANCER; ALGORITHM; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PATIENT; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL (TOPIC); DISEASE SEVERITY; FOLLOW UP; HUMAN; INCIDENCE; MEDICAL RECORD REVIEW; MELANOMA; NEUROTOXICITY; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; SYSTEMATIC REVIEW; TREATMENT RESPONSE; UNITED KINGDOM; CHEMICALLY INDUCED; DISEASE FREE SURVIVAL; MORTALITY; NEUROLOGIC DISEASE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SKIN TUMOR; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; DISEASE-FREE SURVIVAL; HUMANS; IPILIMUMAB; MELANOMA; NERVOUS SYSTEM DISEASES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 85019549399     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdw558     Document Type: Article

References (17)

1. Robert C, Long GV, Brady B et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl JMed 2015; 372(4): 320-330.
2. Weber JS, D'Angelo SP, Minor D et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2015; 16(4): 375-384.
3. Ribas A, Puzanov I, Dummer R et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol 2015; 16(8): 908-918.
4. Robert C, Thomas L, Bondarenko I et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364(26): 2517-2526.
5. Larkin J, Chiarion-Sileni V, Gonzalez R et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015; 373(1): 23-34.
6. Eggermont AMM, Chiarion-Sileni V, Grob J-J et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol 2015; 16(5): 522-530.
7. Robert C, Schachter J, Long GV et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015; 372(26): 2521-2532.
8. Voskens CJ, Goldinger SM, Loquai C et al. The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS One 2013; 8(1): e53745.
9. Zimmer L, Goldinger SM, Hofmann L et al. Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. Eur J Cancer 2016; 60: 210-225.
10. Yervoy-Summary of Product Characteristics. http://www.medicines. org.uk/emc/medicine/24779 (1 July 2016, date last accessed).
11. Opdivo-Summary of Product Characteristics. https://www.medicines. org.uk/emc/medicine/30476 (1 July 2016, date last accessed).
12. Keytruda-Summary of Product Characteristics. https://www.medicines. org.uk/emc/medicine/30602 (1 July 2016, date last accessed).
13. Hughes RAC, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst Rev 2014; 9: CD002063.
14. Raphaël JC, Chevret S, Hughes RAC, Annane D. Plasma exchange for Guillain-Barré syndrome. Cochrane Database Syst Rev 2012; 7: CD001798.
15. Manousakis G, Koch J, Sommerville RB et al. Multifocal radiculoneuropathy during ipilimumab treatment of melanoma. Muscle Nerve 2013; 48(3): 440-444.
16. Thibult M-L, Mamessier E, Gertner-Dardenne J et al. PD-1 is a novel regulator of human B-cell activation. Int Immunol 2013; 25(2): 129-137.
17. Sage PT, Paterson AM, Lovitch SB, Sharpe AH. The coinhibitory receptor CTLA-4 controls B cell responses by modulating T follicular helper, T follicular regulatory, and T regulatory cells. Immunity 2014; 41(6): 1026-1039.